Hudson Bay Capital Management LP Otonomy, Inc. Transaction History

Hudson Bay Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$1.8 - $2.97 $270,000 - $445,500	-150,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$2.6 - $3.95 $267,540 - $406,455	102,900 Added 218.47%	150,000 $413,000
Q2 2018 Aug 13, 2018	SELL	$3.7 - $4.75 $472,878 - $607,073	-127,805 Reduced 73.07%	47,100 $181,000
Q1 2018 May 14, 2018	SELL	$4.05 - $6.1 $101,634 - $153,079	-25,095 Reduced 12.55%	174,905 $735,000
Q4 2017 Feb 12, 2018	BUY	$2.8 - $5.55 $140,000 - $277,500	50,000 Added 33.33%	200,000 $1.11 Million
Q3 2017 Nov 13, 2017	BUY	$3.2 - $20.8 $480,000 - $3.12 Million	150,000	150,000 $488,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.